Pfizer recalls some antidepressants after drug mixup

Pfizer recalls some antidepressants after drug mixup
Action taken after pharmacist found a heart drug among Effexor/Venlafaxine, FDA says.

(HealthDay)—Two lots of Pfizer's antidepressant drug Effexor XR (venlafaxine HCl) are being recalled because they may contain capsules of another drug called Tikosyn (dofetilide), which is used to treat heart rhythm disorders.

The also includes one lot of generic Greenstone brand venlafaxine HCl capsules, the U.S. Food and Drug Administration said Friday.

The agency said that unknowingly taking Tikosyn could have serious and potentially fatal consequences.

The recall is for:

  • one lot of 30-count Effexor XR 150-milligram extended-release capsules,
  • one lot of 90-count Effexor XR 150-milligram extended-release capsules,
  • and one lot of 90-count Greenstone venlafaxine HC1 150-milligram extended-release capsules.

The Pfizer drug lot numbers are V130142 and V130140, and have an expiration date of October 2015. The Greenstone lot number is V130014, which has an expiration date of August 2015.

The voluntary recall comes after a pharmacist found that a bottle of Effexor XR contained one capsule of Tikosyn 0.25 milligram, the FDA said.

The agency advises pharmacists to immediately halt sales of the recalled lots of the drugs and notify customers who've been sold the drugs. Patients with the recalled medicines should contact their doctor and/or return them to their pharmacy.

Patients who have been prescribed Effexor XR/Venlafaxine HCl but think they may have mistakenly taken a Tikosyn capsule should immediately contact their doctor or a hospital, Pfizer said.

They should monitor themselves for signs of abnormal heartbeat and seek medical help if they feel faint, become dizzy, or have a fast heartbeat, the maker said.

For more information about the recall, call Pfizer at 1-800-438-1985, Monday to Thursday 9 a.m. to 8 p.m. ET or Friday from 9 a.m. to 5 p.m. ET.

More information: The U.S. Food and Drug Administration has more about Tikosyn.

More Information

add to favorites email to friend print save as pdf

Related Stories

Pfizer will buy NextWave Pharma for up to $700M

Oct 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Drugmaker Ranbaxy halts generic Lipitor production

Nov 30, 2012

Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were ...

First generic version of cancer drug Doxil approved

Feb 04, 2013

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

11 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments